Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofil Chemicals & Pharmaceuticals Scaled Net Operating Assets Chart
NSE:BIOFILCHEM vs ZTS: Scaled Net Operating Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofil Chemicals & Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofil Chemicals & Pharmaceuticals Scaled Net Operating Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofil Chemicals & Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Biofil Chemicals & Pharmaceuticals's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.00 mean?
Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) has a Scaled Net Operating Assets of 0.00 as of Jun. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors.
Is Biofil Chemicals & Pharmaceuticals' Scaled Net Operating Assets too high?
Biofil Chemicals & Pharmaceuticals' current Scaled Net Operating Assets is 0.00. Overall, Biofil Chemicals & Pharmaceuticals has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biofil Chemicals & Pharmaceuticals' Scaled Net Operating Assets compare to ZTS?
Biofil Chemicals & Pharmaceuticals' Scaled Net Operating Assets of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. Biofil Chemicals & Pharmaceuticals's current Scaled Net Operating Assets is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofil Chemicals & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹49.04, compared to a current price of ₹32.93 — trading 32.9% below its estimated fair value. The current Scaled Net Operating Assets is 0.00. Biofil Chemicals & Pharmaceuticals' overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM), the current Scaled Net Operating Assets is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) Overvalued in 2026?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹32.93 is trading 32.9% below its estimated GF Value™ of ₹49.04.
GuruFocus considers Biofil Chemicals & Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:BIOFILCHEM:
Scaled Net Operating Assets: 0.00
GF Value™: ₹49.04 vs. price of ₹32.93 (32.9% below fair value)
No single metric tells the full story. See the NSE:BIOFILCHEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofil Chemicals & Pharmaceuticals Ltd is an Indian pharmaceutical company. It deals in the manufacturing and trading of pharmaceuticals. Further, the company also deals in providing job work facilities with respect to the manufacturing of pharmaceutical drugs. Its product portfolio comprises basic drugs and pharmaceuticals such as sodium citrate, sodium chloride, ferrous sulphate, micro crystalline cellulose, dicyclomine hydrochloride, and others. The company's operating segments are: Pharma, which derives maximum revenue, and Chemicals. Geographically, it caters to both domestic and international markets.
72GF Score
Get the complete analysis for NSE:BIOFILCHEM
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BIOFILCHEM has been successfully added to your 
